Division of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, 55 Queen St E, Toronto, Ontario M5C 1R6, Canada; Director and Founder, NeuroEconSolutions© (www.neuroeconsolutions.com), Toronto, Canada; Clinical Outcomes and Decision Neuroscience Unit, St Michael's Hospital, University of Toronto, Toronto, Canada; Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Canada.
Clinical Outcomes and Decision Neuroscience Unit, St Michael's Hospital, University of Toronto, Toronto, Canada.
Mult Scler Relat Disord. 2022 Feb;58:103404. doi: 10.1016/j.msard.2021.103404. Epub 2021 Nov 16.
Previous studies in multiple sclerosis (MS) showed that therapeutic inertia (TI) affects 60-90% of neurologists and up to 25% of daily treatment decisions. The objective of this study was to determine the most common factors and attribute levels associated with decisions to treatment escalation in an international study in MS care.
300 neurologists with MS expertise from 20 countries were invited to participate. Participants were presented with 12 pairs of simulated MS patient profiles described by 13 clinically relevant factors. We used disaggregated discrete choice experiments to estimate the weight of factors and attributes affecting physicians' decisions when considering treatment selection. Participants were asked to select the ideal candidate for treatment escalation from modest to higher-efficacy therapies.
Overall, 229 neurologists completed the study (completion rate: 76.3%). The top 3 weighted factors associated with treatment escalation were: previous relapses (20%), baseline expanded disability status scale [EDSS] (18%), and MRI activity (13%). Patient demographics and desire for pregnancy had a modest influence (≤ 3%). We observed differences in the weight of factors associated with treatment escalation between MS specialists and non-MS specialists.
Our results provide critical information on factors influencing neurologists' treatment decisions and should be applied to continuing medical education strategies.
先前的多发性硬化症 (MS) 研究表明,治疗惰性 (TI) 影响 60-90%的神经科医生,高达 25%的日常治疗决策受到影响。本研究的目的是确定在 MS 护理的国际研究中,与治疗升级决策最相关的常见因素和属性水平。
来自 20 个国家的 300 名具有 MS 专业知识的神经科医生受邀参加。参与者被展示了 12 对由 13 个临床相关因素描述的模拟 MS 患者概况。我们使用离散选择实验来估计影响医生在考虑治疗选择时决策的因素和属性的权重。参与者被要求从适度到更高疗效的治疗方案中选择理想的治疗升级候选者。
总体而言,229 名神经科医生完成了研究(完成率:76.3%)。与治疗升级最相关的前 3 个加权因素是:既往复发(20%)、基线扩展残疾状况量表 [EDSS](18%)和 MRI 活动(13%)。患者的人口统计学特征和妊娠意愿的影响较小(≤3%)。我们观察到 MS 专家和非 MS 专家在与治疗升级相关的因素权重方面存在差异。
我们的研究结果提供了影响神经科医生治疗决策的因素的关键信息,应应用于继续医学教育策略。